Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell

被引:17
作者
Chen, Jiang [1 ]
Guo, Xiao-Zhong [1 ]
Li, Hong-Yu [1 ]
Wang, Di [1 ]
Shao, Xiao-Dong [1 ]
机构
[1] PLA, Shenyang Gen Hosp, Dept Gastroenterol, Shenyang 110016, Liaoning, Peoples R China
基金
中国国家自然科学基金;
关键词
Dendritic cell; tumor total RNA; hybrid; pancreatic cancer; cytotoxic T cell; ANTITUMOR IMMUNE-RESPONSES; MESSENGER-RNA; IN-VITRO; IMMUNOTHERAPY; THERAPY; LINES; ELECTROPORATION; ADENOCARCINOMAS; INDUCTION; CYTOKINES;
D O I
10.1177/1535370215571884
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Pancreatic cancer (PC) is a deadly human malignancy. Dendritic cell (DC)-based immunotherapy with whole tumor antigens demonstrates potential efficiency in cancer treatment. Tumor RNA and tumor fusion hybrid cells are sources of whole tumor antigens for preparing DC tumor vaccines. However, the efficacy of these sources in eliciting immune responses against PC has not yet to be directly compared. In the present study, patient-derived PC cells and DCs were fused (DC-tumor hybrids) and primary cultured PC cell-derived total RNA was electroporated into autologous DCs (DC-tumor RNA). The antitumor immune responses induced by DC-tumor hybrids and DC-tumor RNA were compared directly. The results showed that both RNA and hybrid methodologies could induce tumor-specific cytotoxic T lymphocyte (CTL) responses, but pulsing DCs with total tumor RNA could induce a higher frequency of activated CTLs and T-helper cells than fusing DCs with autologous tumor cells. In addition, DC-tumor RNA triggered stronger autologous tumor cell lysis than DC-tumor hybrids. It could be concluded that DCs pulsed with whole tumor RNA are superior to those fused with tumor cells in priming anti-PC CTL responses. Electroporation with total tumor RNA may be more suitable for DC-based PC vaccination.
引用
收藏
页码:1310 / 1318
页数:9
相关论文
共 42 条
[1]   The nature of activatory and tolerogenic dendritic cell-derived signal II [J].
Bakdash, Ghaith ;
Sittig, Simone P. ;
van Dijk, Tjeerd ;
Figdor, Carl G. ;
de Vries, L. Jolanda M. .
FRONTIERS IN IMMUNOLOGY, 2013, 4
[2]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[3]  
Boczkowski D, 2000, CANCER RES, V60, P1028
[4]   TCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct Mechanisms [J].
Borbulevych, Oleg Y. ;
Santhanagopolan, Sujatha M. ;
Hossain, Moushumi ;
Baker, Brian M. .
JOURNAL OF IMMUNOLOGY, 2011, 187 (05) :2453-2463
[5]   The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer [J].
Curry, Jennifer M. ;
Thompson, Kyle J. ;
Rao, Shanti G. ;
Besmer, Dahlia M. ;
Murphy, Andrea M. ;
Grdzelishvili, Valery Z. ;
Ahrens, William A. ;
McKillop, Iain H. ;
Sindram, David ;
Iannitti, David A. ;
Martinie, John B. ;
Mukherjee, Pinku .
JOURNAL OF SURGICAL ONCOLOGY, 2013, 107 (07) :713-722
[6]   Manipulating immune cells for adoptive immunotherapy of cancer [J].
Darcy, Phillip K. ;
Neeson, Paul ;
Yong, Carmen S. M. ;
Kershaw, Michael H. .
CURRENT OPINION IN IMMUNOLOGY, 2014, 27 :46-52
[7]  
Edge S.B., 2010, AJCC cancer staging manual, V649
[8]   Dendritic cell-based cancer immunotherapies [J].
Fujii, Shin-ichiro ;
Takayama, Takuya ;
Asakura, Miki ;
Aki, Kaori ;
Fujimoto, Koji ;
Shimizu, Kanako .
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2009, 57 (03) :189-198
[9]   RNA pulsed dendritic cells: An approach for cancer immunotherapy [J].
Garg, Neeraj Kumar ;
Dwivedi, Priya ;
Prabha, Punit ;
Tyagi, Rajeev K. .
VACCINE, 2013, 31 (08) :1141-1156
[10]  
Geiger Christiane, 2005, J Transl Med, V3, P29